TY - JOUR
T1 - Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease
T2 - Systematic Review and Consensus Conference
AU - on behalf of the International Organization for the Study of Inflammatory Bowel Diseases [IOIBD]
AU - Hammoudi, Nassim
AU - Sachar, David
AU - D'Haens, Geert
AU - Reinisch, Walter
AU - Kotze, Paulo Gustavo
AU - Vermeire, Severine
AU - Schölmerich, Jürgen
AU - Kamm, Michael A.
AU - Griffiths, Anne
AU - Panes, Julian
AU - Ghosh, Subrata
AU - Siegel, Corey A.
AU - Bemelman, Willem
AU - O'Morain, Colm
AU - Steinwurz, Flavio
AU - Fleshner, Phillip
AU - Mantzaris, Gerassimos J.
AU - Sands, Bruce
AU - Abreu, Maria T.
AU - Dotan, Iris
AU - Turner, Dan
AU - Dignass, Axel
AU - Allez, Matthieu
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site - for further information please contact [email protected].
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Background: Outcomes after ileocolonic resection in Crohn's disease [CD] are heterogeneous, and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease [IOIBD] aimed to standardise postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials, and to define those which could be used in trials or registries. Methods: Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting. Recommendations and statements were revised based on the voters' comments during a consensus hybrid conference open to all IOIBD members. If no agreement was reached after two rounds of voting, the statement was excluded. Results: In the systematic review, 3071 manuscripts were screened of which 434 were included. Sixteen recommendations were identified, of which 11 were endorsed. Recommendations and statements include that endoscopy remains the gold standard and should be used as a short-term primary endpoint in both observational cohorts and randomised controlled trials. Clinical symptoms classically used in clinical trials for luminal CD are not reliable in this specific situation. For that reason, longer-term endpoints should be based on the evidence of macroscopic inflammation assessed by imaging techniques, endoscopy, or as reflected by the presence of complications. Conclusions: Agencies recommend the use of clinical evaluations, as in the case of luminal CD, and do not recognise primary endpoints based solely on endoscopy. This consensus has led to agreement on the need to define postoperative endoscopy-based and/or imaging-based endpoints.
AB - Background: Outcomes after ileocolonic resection in Crohn's disease [CD] are heterogeneous, and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease [IOIBD] aimed to standardise postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials, and to define those which could be used in trials or registries. Methods: Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting. Recommendations and statements were revised based on the voters' comments during a consensus hybrid conference open to all IOIBD members. If no agreement was reached after two rounds of voting, the statement was excluded. Results: In the systematic review, 3071 manuscripts were screened of which 434 were included. Sixteen recommendations were identified, of which 11 were endorsed. Recommendations and statements include that endoscopy remains the gold standard and should be used as a short-term primary endpoint in both observational cohorts and randomised controlled trials. Clinical symptoms classically used in clinical trials for luminal CD are not reliable in this specific situation. For that reason, longer-term endpoints should be based on the evidence of macroscopic inflammation assessed by imaging techniques, endoscopy, or as reflected by the presence of complications. Conclusions: Agencies recommend the use of clinical evaluations, as in the case of luminal CD, and do not recognise primary endpoints based solely on endoscopy. This consensus has led to agreement on the need to define postoperative endoscopy-based and/or imaging-based endpoints.
KW - IBD
KW - biotherapy
KW - clinical trials
KW - surgery
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85195227961&partnerID=8YFLogxK
U2 - 10.1093/ecco-jcc/jjad205
DO - 10.1093/ecco-jcc/jjad205
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 38112601
AN - SCOPUS:85195227961
SN - 1873-9946
VL - 18
SP - 943
EP - 957
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 6
ER -